Latest Intraocular pressure Stories
New research finds that older, overweight women may be at lower risk for glaucoma than their thinner peers.
Cumbersome glaucoma tests that require a visit to the ophthalmologist could soon be history thanks to a home test developed by a UA engineer.
Two new studies provide hopeful information for those at risk of age-related macular degeneration (AMD) and glaucoma.
Seniors interested in lifestyle choices that help protect vision will be encouraged by a Johns Hopkins School of Medicine study, and people concerned about glaucoma can take heart from work on early detection by the University of Miami Miller School of Medicine.
Corneal arcus, a condition in which a ring of lipids builds up around the cornea, appears common among middle-age and older adults and may be associated with elevated eye pressure, according to a report in the November issue of Archives of Ophthalmology, one of the JAMA/Archives journals.
A tool, widely regarded as the "gold standard," but often deemed to be too expensive, cuts needless referrals for suspected glaucoma, indicates preliminary research published online in the British Journal of Ophthalmology.
- SYL040012 is a new compound arising from Sylentis' research in ophthalmological disorders. - It is indicated for treating ocular hypertension and preventing glaucoma. - SYL040012 is a form of interference RNA (RNAi). - It reduces intraocular pressure by inhibiting the expression of b-adrenergic receptors. MADRID, Sept.
Patients with glaucoma appear to have more rapid visual field change if they are older or if they have abnormal levels of anticardiolipin antibody (an antibody directed against a certain protein in the body).
This month's Ophthalmology journal includes surprising research from the Massachusetts Eye and Ear Infirmary on the relation of body weight to the risk for glaucoma.
MADRID, July 6 /PRNewswire/ -- Sylentis, a biopharmaceutical subsidiary of Grupo Zeltia (MC: ZEL) and a pioneer in the research and development of new drugs based on gene silencing (interference RNA, RNAi), has completed Phase Ia of its first clinical trial with SYL040012 in the form of ophthalmic drops to treat elevated intraocular pressure and glaucoma.
- A volcanic mudflow.